Search for a trial

A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) after Completion of Platinum-based First Line Chemotherapy

The aim of the study is to compare overall survival (OS) and Blinded Independent Central Review (BICR)-assessed progression free survival (PFS), of nivolumab, and nivolumab in combination with ipilimumab, versus placebo in subjects with ED-SCLC…

Safety assessment of cold gas plasma on intact skin

Primary objective1. To test the safety of cold plasma treatment: SAE in * 10% of participants, no pain (VAT * 2) and no local skin reaction: redness, blister formation, pain or itching. Secondary objectives:The effect of cold plasma treatment on : 1…

Targeted therapy with imatinib for treatment of poor prognosis mesenchymal-type resectable colon cancer: a proof-of-concept study in the preoperative window period.

The main objective is to study the effects of targeted PDGFR and cKIT signalling inhibition with imatinib on gene expression profiles of colon tumours with a high chance of having the mesenchymal phenotype.

A Randomized, Double-blind Study To Evaluate the Efficacy and
Safety of Cabozantinib (XL184) at 60 mg/Day Compared to
140 mg/Day in Progressive, Metastatic Medullary Thyroid
Cancer Patients

The objective of this study is to evaluate the efficacy of oral cabozantinib at adaily dose of 60 mg compared with 140 mg in subjects with progressive,metastatic MTC.

Phase IB Study of MK-3475 in Subjects with Select Advanced Solid Tumors

The primary objective of the trial is to evaluate a preliminary signal of potential anti-tumor activity of MK-3475 in subjects with PD-L1 positive advanced solid tumors. Secondary objectives include safety and tolerability, progression-free survival…

Pilot study on the determination of tumor concentrations of protein kinase inhibitors in patients with newly diagnosed high-grade glioma

The main objective of this pilot study is to determine PKI concentration in tumor tissue after approximately two weeks of treatment.

Phase I dose-escalation study of S 81694 administered intravenously in adult patients with advanced/metastatic solid tumours

Primary Objective: to determine the maximum tolerated dose (MTD) and the associated dose-limiting toxicities (DLTs) of S 81694.Secondary Objectives:- To define the safety and tolerability profile of S 81694;- To define the recommended phase II dose…

A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-
936558) for Subjects with Histologically Confirmed Stage III
(unresectable) or Stage IV Melanoma Progressing After Prior Treatment
Containing an Anti-CTLA-4 Monoclonal Antibody

The primary objective of this trial are:- To determine the incidence of high-grade (CTCAE v4.0 Grade 3 orhigher), treatment related, select adverse events in patients withhistologically confirmed stage III (unresectable) or stage IV melanomaand…

The changing over time of ascorbic acid after chemotherapy and the correlation between ascorbic acid and the recovery of the immune cells after chemotherapy in patients receiving intensive clinical chemotherapy for acute leukemia and high dose chemotherapy with autologous stem cell rescue and in outpatients receiving relatively mild chemotherapy for lung cancer and colon cancer.

The aim of this study is to evaluate the changing over time of AA levels in plasma and in leukocytes before and during chemotherapy treatment for several different groups of patients and compare that to healthy controls.

A randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracycLines-based chemotherapy (AIDA regimen) for patients with newly diagnosed, high-risk acute prOmyelocytic leukemia.

To compare event-free survival (EFS) of the experimental treatment arm including ATO/ATRA and idarubicin with standard treatment based on ATRA plus chemotherapy (AIDA regimen).

Multicenter phase I/IIa study using T-cell receptor gene therapy in metastatic melanoma

To study the safety of the adoptive transfer of autologous T cells modified with a Mart-1 specific TCR in advanced stage (uveal) melanoma patients with disease progression upon standard cancer therapy. In addition, the toxicity according to CTC…

International randomized phase III study on the treatment of children and adolescents with refractory or relapsed acute myeloid leukemia

The main objective of this treatment protocol is to study the efficacy on the treatment response after adding a single gift of Mylotarg. Furthermore, monitoring of toxicity and long term efficacy is also important.

Effectiveness of blended therapy for psychological distress in colorectal cancer survivors: The CORRECT multicenter trial

Intervention studies for distress in CRCS are scarce. The CORRECT intervention (COloRectal canceR distrEss reduCTion) will be aimed at decreasing psychological distress through participatory healthcare. The context of healthcare is rapidly changing…

Adjuvant hepatic arterial infusion pump chemotherapy after resection of colorectal liver metastases - a feasibility study

Primary Objective: The first objective of this study is to evaluate the safety and feasibility of adjuvant HAIP chemotherapy after resection of CLM in 2 centres in the Netherlands.Secondary Objective(s): The second objective is to determine whether…

A PHASE 1/2 MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND REGIMEN OF DURVALUMAB (MEDI4736) IN COMBINATION WITH LENALIDOMIDE (LEN) WITH AND WITHOUT DEXAMETHASONE (DEX) IN SUBJECTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)

Main objective:Determine the recommended dose of durvalumab in combination withLEN +/- dex in subjects with NDMM.Secondary objectives:- Evaluate the safety and preliminary efficacy of durvalumab incombination with LEN +/- dex in subjects with NDMM-…

A phase 2, single arm, multi center trial evaluating the efficacy of the combination of sirolimus and cyclophosphamide in metastatic or unresectable myxoid liposarcoma and chondrosarcoma.

- To evaluate the treatment efficiency by time to progression according to RECIST 1.1

Improving the tolerability of the oral targeted anti-cancer drug pazopanib by food intake (DIET).

Part APrimary objective:To determine the equivalent dose of pazopanib when taken with a continental breakfast compared to 800 mg in fasted state.Secondary objective:To monitor the occurrence of adverse events of pazopanib with and without food…

Phase I/II study with the combination of dacomitinib and PD-0325901 in metastatic KRAS mutation positive non-small cell lung cancer

Primary objectivesPhase I:To determine the recommended phase 2 dose (RP2D) of the dacomitinib-PD-0325901 combination in patients with KRASm NSCLC Phase II:To determine the progression free survival of the dacomitinib/PD-0325901 combination compared…

Transarterial embolization of non-bleeding hepatocellular adenomas: a pilot study

To gain insight into the effects of TAE on HCAs and their behavior post-embolisation.

Distribution of NIlotinib in semen in men treated for chronic Myeloid leukaemiA

This study is designed to determine the level of nilotinib detectable in seminal fluid of men treated with this tyrosine kinase inhibitor and in order to form an advise on the use of physical barriers like, condoms, to protect sexual partners from…